Shots:

• The approval is based on P-II Brigatinib-2001 (J-ALTA) assessing Alunbrig in 72 Japanese patients with ALK+ NSCLC and P-III AP26113-13-301 (ALTA-1L) study assessing Alunbrig (180mg- qd with seven-day lead-in at 90mg- qd) vs crizotinib (250mg- bid) in 275 patients with ALK+ advanced NSCLC prior not treated with an ALK inhibitor
• The therapy showed effectiveness in patients undergoing 1L & 2L treatment for ALK+ NSCLC including efficacy in patients with brain metastases.
• Alunbrig is a potent and selective next-generation TKI designed to target ALK molecular alterations and is approved in 30+ countries including the US & EU

 ­ Ref: Takeda | Image: Takeda